$7.1 BILLION ACQUISITION: ILLUMINA ACQUIRING ONCOLOGY DIAGNOSTICS INNOVATOR GRAIL
Acquisition pairs Grail with one of its founding investor organizations and forms a cancer care genetics research leader
Gene sequencing leader Illumina Inc. (NASDAQ: ILMN) is investing $7.1 billion in cash and stock to buy oncology diagnostics brain trust Grail Inc. in a pairing of two west coast life sciences companies. Based in San Diego, California, Illumina is a leader in the development, manufacturing and marketing of integrated systems for the analysis of genetic and biological testing.
Headquartered in Menlo Park, California, healthcare technology enterprise Grail is backed by Microsoft founder Bill Gates and Amazon founder Jeff Bezos. Illumina originally founded Grail in 2016 with the intention of it focusing on the development of blood tests that can identify early-stage cancers and it has forged a larger role in precision medicine plus other advanced sciences.
By pairing itself with Grail, Illumina will accelerate its development of gene-sequencing technology for the diagnosis and treatment of cancer patients while fortifying its pipeline with additional product candidates.
Grail is backed by an array of prominent investors
While Illumina helped in the development of Grail as an organization, it is accompanied by several other notable companies that invested in Grail’s further growth. The list of investor stakeholders in Grail includes:
- Arch Venture Partners
- Bezos Ventures
- Bill Gates
- Bristol-Meyers Squibb
- Johnson & Johnson
- McKesson Ventures
- Sutter Hill Ventures
- Varian Medical Ventures
As an innovator in oncology, Grail’s research is highly specialized
Grail’s genomic medicine research involves their collaboration with academic and community hospitals to enroll thousands of patients in their clinical studies.
Enormous amounts of data are required to develop and validate blood tests that pair genomic sequencing with intricate computational algorithms to identify cancer-specific patterns in the early stages of formation. One of their primary new product platforms is known as Galleri.
Current clinical trial studies underway by Grail include:
- Circulating Cell-free Genome Atlas Study (a prospective, observational, longitudinal, study characterizing the landscape of genomic cancer signals in the blood of people with and without cancer)
- Pathfinder (multi-cancer early detection testing)
- Strive (Underway in the UK, it is centered on multi-cancer testing including lung cancer detection)
- Summit (Multi-cancer detection including patients with a history of smoking)
Illumina tackles advanced research in numerous sectors while generating significant sales
The bioscience exploration Illumina has underway is impressive. Its commercial products and research & development initiatives encompass:
- Cellular and molecular biology
- Complex diseases
- Genetic and rare diseases
- Reproductive health
Their core sequencing and microarray product lines are further complemented by its Illumina COVIDSeq Test. It is a high-throughput NGS test that detects SARS-CoV-2 (COVID-19) in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs.
Illumina accelerates clinical and commercial plans for growth
Founded in 1998, Illumina produced over $3.5 billion in sales in 2019. As a startup company, Grail had reportedly filed for an initial public offering (IP0) and generated less than $100 million in 2019 annual sales. Moving forward, Illumina will be a contending innovator in gene therapy by add Grail and its many clinical and commercial attributes.
Thank you for reading this story
I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.
As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.
To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.
Visit and connect…
Contact me today for your healthcare content writing and content strategy needs for medical, business, academic, patient and consumer healthcare audiences…